Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 25, No 30 (October 20), 2007: pp. 4757-4764
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.12.1087

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leibovich, B. C.
Right arrow Articles by Kwon, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leibovich, B. C.
Right arrow Articles by Kwon, E. D.
Related Articles
Right arrowRelated Correspondence

Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma

Bradley C. Leibovich, Yuri Sheinin, Christine M. Lohse, R. Houston Thompson, John C. Cheville, Jan Zavada, Eugene D. Kwon

From the Departments of Urology, Health Sciences Research, Laboratory Medicine and Pathology, and Immunology, Mayo Medical School and Mayo Clinic, Rochester, MN; and the Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic

Address reprint requests to Eugene D. Kwon, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: kwon.eugene{at}mayo.edu

Purpose: Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up.

Patients and Methods: We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models.

Results: There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (≤ 85% tumor cells positive) expression, and 567 (77.7%) exhibited high (> 85% tumor cells positive) expression. Univariately, low CAIX expression was associated with increased risk of RCC death relative to high expression (risk ratio = 1.65; P < .001). However, low CAIX expression was not associated with RCC death after adjusting for nuclear grade or coagulative tumor necrosis. Additionally, we observed CAIX expression in a number of extrarenal organs.

Conclusion: CAIX is strongly expressed by ccRCC. Although CAIX is associated with outcome in patients with ccRCC, it is not an independent prognostic marker. Furthermore, CAIX expression is apparent in extrarenal organs. As such, exploitation of CAIX as a prognostic marker and therapeutic target merits additional consideration.

Supported in part by the Richard M. Schulze Family Foundation, the Commonwealth Foundation for Cancer Research, and the Helen and Martin Kimmel Foundation.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Related Correspondence

  • Carbonic Anhydrase IX As a Predictive Biomarker for Clear Cell Renal Cell Carcinoma
    Allan J. Pantuck, Tobias Klatte, David Seligson, Michael Atkins, and Arie Belldegrun
    JCO 2008 26: 3105-3107 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
A. H. Brouwers, P. F.A. Mulders, and W. J.G. Oyen
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma and Normal Tissues: Experiences From (Radio) Immunotherapy
J. Clin. Oncol., August 1, 2008; 26(22): 3808 - 3809.
[Full Text] [PDF]


Home page
JCOHome page
P. Skapa, L. Hyrsl, J. Zavada, J. Soukup, and J. Zamecnik
Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinomas Negatively Correlates With the Proportion of the Granular Cell Component
J. Clin. Oncol., August 1, 2008; 26(22): 3809 - 3811.
[Full Text] [PDF]


Home page
JCOHome page
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon
In Reply
J. Clin. Oncol., August 1, 2008; 26(22): 3811 - 3812.
[Full Text] [PDF]


Home page
JCOHome page
A. J. Pantuck, T. Klatte, D. Seligson, M. Atkins, and A. Belldegrun
Carbonic Anhydrase IX As a Predictive Biomarker for Clear Cell Renal Cell Carcinoma
J. Clin. Oncol., June 20, 2008; 26(18): 3105 - 3107.
[Full Text] [PDF]


Home page
JCOHome page
B. C. Leibovich, Y. Sheinin, C. M. Lohse, R. H. Thompson, J. C. Cheville, J. Zavada, and E. D. Kwon
In Reply
J. Clin. Oncol., June 20, 2008; 26(18): 3107 - 3109.
[Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
W. K. Rathmell, W. M. Stadler, and B. I. Rini
Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 192 - 198.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online